Table 3 Preferred terms of the treatment-related adverse events (TRAEs)
TRAE | Grade 1/2 | Grade 3 | Grade 4 | Total |
|---|---|---|---|---|
Hypertriglyceridemia | 37 (62%) | 1 (2%) | 1 (2%) | 39 (65%) |
Hypertension | 19 (32%) | 15 (25%) | 0 (0%) | 34 (57%) |
Hypercholesterolemia | 31 (52%) | 0 (0%) | 0 (0%) | 31 (52%) |
Proteinuria | 30 (50%) | 0 (0%) | 0 (0%) | 30 (50%) |
Diarrhea | 27 (45%) | 3 (5%) | 0 (0%) | 30 (50%) |
Hand-foot syndrome | 19 (32%) | 2 (3%) | 0 (0%) | 21 (35%) |
Hypothyroidism | 20 (33%) | 0 (0%) | 0 (0%) | 20 (33%) |
Elevated thyroid stimulating hormone | 17 (28%) | 0 (0%) | 0 (0%) | 17 (28%) |
Rash | 16 (27%) | 0 (0%) | 0 (0%) | 16 (27%) |
Elevated alanine transaminase | 13 (22%) | 2 (3%) | 0 (0%) | 15 (25%) |
Elevated low-density lipoprotein | 13 (22%) | 0 (0%) | 0 (0%) | 13 (22%) |
Elevated aspartate aminotransferase | 11 (18%) | 1 (2%) | 0 (0%) | 12 (20%) |
Fecal occult blood | 10 (17%) | 0 (0%) | 0 (0%) | 10 (17%) |
Bleeding gums | 9 (15%) | 1 (2%) | 0 (0%) | 10 (17%) |
Oral mucositis | 8 (13%) | 1 (2%) | 0 (0%) | 9 (15%) |
Urine occult blood | 9 (15%) | 0 (0%) | 0 (0%) | 9 (15%) |
Hematuria | 9 (15%) | 0 (0%) | 0 (0%) | 9 (15%) |
Nasal bleeding | 8 (13%) | 0 (0%) | 0 (0%) | 8 (13%) |
Hyperuricemia | 6 (10%) | 0 (0%) | 0 (0%) | 6 (10%) |
Sinus bradycardia | 2 (3%) | 1 (2%) | 0 (0%) | 3 (5%) |
Thrombocytopenia | 3 (5%) | 0 (0%) | 0 (0%) | 3 (5%) |
Hyperbilirubinemia | 1 (2%) | 0 (0%) | 0 (0%) | 1 (2%) |
Hemoptysis | 1 (2%) | 0 (0%) | 0 (0%) | 1 (2%) |
Increased creatinine | 1 (2%) | 0 (0%) | 0 (0%) | 1 (2%) |
Acute coronary syndrome | 0 (0%) | 1 (2%) | 0 (0%) | 1 (2%) |
Intracranial hypertension | 0 (0%) | 1 (2%) | 0 (0%) | 1 (2%) |
Myocardial infarction | 0 (0%) | 1 (2%) | 0 (0%) | 1 (2%) |
Thromboembolic events | 0 (0%) | 1 (2%) | 0 (0%) | 1 (2%) |